Background
arthrodesis
Spinal fusion is commonly performed to treat various spinal conditions, and the rate of these procedures have been increasing faster than other orthopedic procedures: a 137% increase was reported in the annual number of spinal fusion discharges between 1998 and 2008 in the United States, whereas laminectomy, and hip and knee arthroplasty increased by 11.3%, 49.1%, and 126.8% respectfully [The primary goal of spinal fusion therapy is to achieve solid bony arthrodesis [A variety of bone graft alternatives are commercially available; however, few substitutes contain all the essential components required for successful arthrodesis [ViBone VBM is a next generation human cellular allograft bone matrix comprised of the same bone-forming elements as ICBG and has been employed for bone repair in spinal, orthopedic, maxillofacial, and other various procedures since it was commercially available per the FDA as a human cells, tissues, and cellular and tissue-based product (HCT/P) in 2017. The unique features of this VBM are due to optimized manufacturing processes to improve handling characteristics, delivering cohesiveness and ease of molding for various implantation sites, and enhance osteogenic potential by preserving cellular health and minimizing apoptotic activity within the allograft. The aim of this study was to collect our real-world clinical experience with ViBone in various spinal fusion procedures.